Evidence map›Paper›PMID 31335677›Full record

SynthesisMedicine2019

Effects of febuxostat on renal function in patients with chronic kidney disease: A systematic review and meta-analysis.

Tsu-Chen Lin, Lie Yee Hung, Ying-Chun Chen, Wei-Cheng Lo, Chun Hung Lin, Ka-Wai Tam, Mei-Yi Wu

Open access · goldAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
4.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Review
  6. Article
  7. Observational
  8. Review
  9. Review
  10. Review
  11. Comparative Cardiovascular Risks of Febuxostat and Allopurinol in Patients with Diabetes Mellitus and Chronic Kidney Disease.Medical science monitor : international medical journal of experimental and clinical research · 2024
    Observational
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Tsu-Chen LinSchool of Medicine, College of Medicine, Taipei Medical University, Taipei.
Lie Yee HungDivision of Nephrology, Department of Internal Medicine, Taipei Medical University-Shuang Ho Hospital.
Ying-Chun ChenDepartment of Pharmacy, Taipei Medical University-Shuang Ho Hospital, New Taipei City.
Wei-Cheng LoInstitute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei.
Chun Hung LinDepartment of Orthopedics, Far Eastern Memorial Hospital.
Ka-Wai TamCenter for Evidence-Based Health Care, Taipei Medical University-Shuang Ho Hospital.
Mei-Yi WuDivision of Nephrology, Department of Internal Medicine, Taipei Medical University-Shuang Ho Hospital.
Taipei Medical University-Shuang Ho Hospital · TWNational Taiwan University · TWFar Eastern Memorial Hospital · TWTaipei Medical University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

objectiveHyperuricemia has been proven to be an independent risk factor for chronic kidney disease (CKD). However, the role of hyperuricemia in the progression of CKD remains unclear. Thus, we performed a systematic review and meta-analysis to evaluate the efficacy and safety of febuxostat, a first line urate-lowering agent, in CKD patients with hyperuricemia.

methodsWe have systematically searched for randomized controlled trials assessing the efficacy and safety of febuxostat versus control in CKD patients with hyperuricemia through MEDLINE, PubMed, EMBASE, and Cochrane databases. All statistical analyses were conducted by using the statistical package Review Manager, version 5.3.5. Heterogeneity was assessed using the Cochrane Q and I tests and summary statistics were reported with 95% confidence interval. Two-tailed test was used for analysis and a P value of <.05 is considered statistically significant.

resultsEleven eligible trials with 1317 participants were included in the meta-analysis. A significant reduction in serum uric acid was found in the febuxostat treated group. Also, a significant higher eGFR was found in the febuxostat treated group among CKD stage 3 and 4 patients. No significant difference of major complication or death was identified between treatment and control groups.

conclusionsThe meta-analysis showed that other than its urate-lowering effect, febuxostat presented a reno-protective effect in CKD patients. More studies with larger sample sizes and higher quality are required to clarify the role of febuxostat use in the progression of CKD.

Indexed as

Renal Insufficiency, ChronicDisease ProgressionFebuxostatGlomerular Filtration RateGout SuppressantsHumansUric AcidFebuxostatGout SuppressantsUric Acid

Identifiers

PMID31335677
PMCPMC6709169
OpenAlexW2963646943

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.